2nd Circ. Won't Revive Off-Label Ad Suit Against Taro
The Second Circuit on Tuesday refused to revive claims that Taro Pharmaceutical USA Inc. promoted off-label uses of a heart medication, finding that none of the claims against the drugmaker were...To view the full article, register now.
Already a subscriber? Click here to view full article